No Data
Tuoxin Pharmaceutical: 2024 Annual Report
Tuoxin Pharmaceutical: Report for the first quarter of 2025
Tuoxin Pharmaceutical: 2024 Annual Report Summary
Taoxin Pharmaceutical (301089.SZ): Net loss of 3.5647 million yuan in the first quarter.
On April 25, Gelonghui reported that Toxin Pharmaceutical (301089.SZ) announced its first quarter report for 2025. During the reporting period, revenue reached 96.9947 million yuan, a decrease of 10.46% year-on-year; the net income attributable to shareholders of the listed company was -3.5647 million yuan, and the net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was -5.9527 million yuan, with an EPS of -0.03 yuan.
Tuo Xin Pharmaceutical (301089.SZ): The wholly-owned subsidiary's application for the listing of the Active Pharmaceutical Ingredient Olaparib has been approved.
On March 6th, Gelonghui reported that Tuoxin Pharmaceutical (301089.SZ) announced that recently, its wholly-owned subsidiary, Xinxiang Pharmaceutical Co., Ltd. (referred to as "Xinxiang Pharmaceutical"), received the "Approval Notice for the Listing Application of Chemical Raw Materials for Olaparib" issued by the National Medical Products Administration (Acceptance No.: CYHS2360686), which has been publicly announced on the official website of the National Medical Products Administration's Drug Review Center. Olaparib is mainly used for advanced epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer associated with germline or somatic BRCA mutations (gBRCAm or sBRCAm).
The employee shareholding platform plan of Tuoxin Pharmaceutical will fully Shareholding all shares within three months ｜ Quick read of the announcement.
① Evers, a Shareholder of Toxin Pharmaceutical, intends to sell all the shares it Holds. ② Evers is not only the employee shareholding platform of Toxin Pharmaceutical, but also a concerted party with the company's controlling Shareholder and actual controller, Yang Xining. ③ There are intricate relationships between Evers and Yang Xining.